Authors
Loading...
Retrospective cohort assessed treatment patterns and discontinuation reasons for CLL patients after switching from acalabrutinib to zanubrutinib, highlighting toxicity as a primary reason.
Choksi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: